Copyright © 1993 by the European Society of Cardiology.
© 1993 The European Society of Cardiology
Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
University Department of Cardiology Tours, France for the flurbiprofen French trial
Received 25 July 1991; revised 22 January 1993; .
Correspondence: M. L. Brochier, University Department of Cardiology. CHU Tours 37044, France
Abstract
Thirty-eight coronary care units (CCUs) in France participated in this double-blind, placebo-controlled, multicentre study to assess the efficacy of flurbiprofen, a non-steroidal anti-inflammatory agent (NSAID) with potent anti-platelet activity (FAA), in the prevention and recurrence of myocardial infarction (MI) and reocclusion of the infarct-related artery (IRA) in patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptoms. A coronary angiogram was performed within the first 24 h to confirm successful reperfusion. Two hundred and thirty-three patients (group 1) were randomly allocated to flurbiprofen 50 mg twice daily and 228 patients (group 2) to placebo. All patients complied with the entry criteria, and drug treatment was commenced within 48 h of MI. Patients were assessed at 3 weeks, 3 months and 6 months, data being recorded on major clinical events and survival status.
Overall mortality was low (1.1%) and similar for both groups, confirming the benefit of early reperfusion therapy. The reinfarction rate documented during the 6-month follow-up was 3% (7/233) in group 1 and 10.5% (24/228) in group 2 (P<0.001).
The need for coronary angioplasty and / or coronary bypass graft was decreased by 51% (group 1:39/233 = 17%; group 2: 75/228 = 33%) (P<0.001). Coronary angiogram at 6 months showed a similar reocclusion rate between treatments.
Flurbiprofen appears to be an effective drug for the prevention of reinfarction after coronary reperfusion and in reducing the need for secondary revascularization procedures. It may offer advantages over aspirin, but comparable efficacy remains to be established.
Key Words: Flurbiprofen • acute myocardial infarction • secondary prevention • reocciusion
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Waksman, A. Brody, and S. D Phillips Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe? Ann. Pharmacother., July 1, 2007; 41(7): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis, June 1, 2007; 66(6): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Kearney, C. Baigent, J. Godwin, H. Halls, J. R Emberson, and C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, June 3, 2006; 332(7553): 1302 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bainbridge, D. C. Cheng, J. E. Martin, R. Novick, and The Evidence-Based Perioperative Clinical Outcomes NSAID-analgesia, pain control and morbidity in cardiothoracic surgery: [L'analgesie avec des AINS, le controle de la douleur et la morbidite en chirurgie cardiothoracique] Can J Anesth, January 1, 2006; 53(1): 46 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kimmel, J. A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B. L. Strom Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction Ann Intern Med, February 1, 2005; 142(3): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Patel and K. C. Goldberg Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction Arch Intern Med, April 26, 2004; 164(8): 852 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kimmel, J. A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B. L. Strom The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin J. Am. Coll. Cardiol., March 17, 2004; 43(6): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Layton, E. Heeley, K. Hughes, and S. A. W. Shakir Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data Rheumatology, November 1, 2003; 42(11): 1342 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Hawkey and M J S Langman Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors Gut, April 1, 2003; 52(4): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bak, M. Andersen, I. Tsiropoulos, L. A. Garcia Rodriguez, J. Hallas, K. Christensen, D. Gaist, and A. I. Qureshi Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nested Case-Control Study * Editorial Comment Stroke, February 1, 2003; 34(2): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Watson, T. Rhodes, B. Cai, and H. A. Guess Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis Arch Intern Med, May 27, 2002; 162(10): 1105 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Catella-Lawson, M. P. Reilly, S. C. Kapoor, A. J. Cucchiara, S. DeMarco, B. Tournier, S. N. Vyas, and G. A. FitzGerald Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin N. Engl. J. Med., December 20, 2001; 345(25): 1809 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mukherjee, S. E. Nissen, and E. J. Topol Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors JAMA, August 22, 2001; 286(8): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF]
|
|
|
|
|
|
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. B. Ferraz, C. J. Hawkey, M. C. Hochberg, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis N. Engl. J. Med., November 23, 2000; 343(21): 1520 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]
|
|
|
|
|
|
Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Konstam, M. R. Weir, A. Reicin, D. Shapiro, R. S. Sperling, E. Barr, and B. J. Gertz Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Circulation, November 6, 2001; 104(19): 2280 - 2288. [Abstract] [Full Text] [PDF]
|
|